Peer-reviewed article

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Ahmed M iD, Cabrera P, Doherty T, Himedan M, Kern DM iD, Turkoz I, Sanacora G

The American journal of psychiatrySep 1, 20260 citationsDOI: 10.1176/appi.ajp.20251203

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

Major Depressive DisorderDepressive DisordersKetamine/esketamine

View paper

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025